Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Disease

Neural stem cells obtained from patient donor iPSCs and isogenic disease models with neurodegenerative disease-associated mutations.

Alzheimer's Disease and Frontotemporal Dementia

Alzheimer's disease (AD) is a neurodegenerative condition that is strongly linked with aging and is responsible for 60 to 70% of all dementia cases.

Accounting for around 2 to 3% of AD cases, early onset Alzheimer's disease is a hereditary condition that is strongly linked with mutations in presenilin-1 (PSEN1), amyloid precursor protein (APP) and presenilin-2 (PSEN2) genes.

Late onset Alzheimer's disease arises after the age of 65 and is responsible for the wide majority of cases. A mixture of factors heightens the risk of developing Alzheimer's disease. A strong risk factor is having two copies of the APOE4 allele, which heightens the risk of getting late onset Alzheimer's disease by around 15 times.

Frontotemporal dementia (FTD) refers to a range of clinical diseases that may have many varied underlying pathologies. Frontotemporal dementia can be infrequent or linked to mutations in the MAPT (microtubule-associated protein tau) and progranulin genes, and C9ORF72 repeat expansions.

These genetic mutations can cause an accumulation of TDP43 protein or tangles of MAPT (tau) protein. At the moment, there are no accepted treatments or dependable biomarkers for frontotemporal dementia.

There is a requirement for in vitro human cell models for frontotemporal dementia and Alzheimer's disease that can be utilized to advance research and help in developing new drugs to treat these disorders.

Human iPSC-derived Neural Stem Cells from Alzheimer’s Disease Patients

Fibroblasts derived from patients who had been clinically diagnosed with Alzheimer's disease were reprogrammed to iPSCs utilizing the Axol footprint-free episomal reprogramming process and then were differentiated to neural stem cells utilizing the Axol chemically-defined cortical neural induction method.

Neural stem cells are accessible from Alzheimer's patients with mutations in the presenilin-1 (PSEN1) and presenilin-2 (PSEN2) genes along with a patient homozygous for the APOE4 allele. Neural stem cells from healthy donor iPSCs are also available as adequate controls.

Cat. No. Product Name Starting Material Quantity
ax0111 Human iPSC-Derived Neural Stem Cells - Alzheimer's Disease Patient (APOE4 HOM) Fibroblasts (87 Yr Female) 1.5 million cells & Neural Plating-XF Medium
ax0112 Human iPSC-Derived Neural Stem Cells - Alzheimer's Disease Patient (PSEN1 L286V) Fibroblasts (38 Yr Female) 1.5 million cells & Neural Plating-XF Medium
ax0113 Human iPSC-Derived Neural Stem Cells - Alzheimer's Disease Patient (PSEN1 M146L) Fibroblasts (53 Yr Male) 1.5 million cells & Neural Plating-XF Medium
ax0114 Human iPSC-Derived Neural Stem Cells - Alzheimer's Disease Patient (PSEN1 A246E) Fibroblasts (31 Yr Female) 1.5 million cells & Neural Plating-XF Medium
       
ax0018 Human iPSC-Derived Neural Stem Cells (Healthy male donor) Fibroblasts (74 Yr Donor) 1.5 million cells & Neural Plating-XF Medium
ax0019 Human iPSC-Derived Neural Stem Cells (Healthy female donor) Fibroblasts (64 Yr Donor) 1.5 million cells & Neural Plating-XF Medium

 

Isogenic Human iPSC-derived Neural Stem Cells

Utilizing the CRISPR-Cas9 gene editing technology, disease-associated mutations were added to iPSCs which were then differentiated to neural stem cells employing Axol’s fully defined cortical neural induction method.

Isogenic control neural stem cells are also accessible. They enable highly targeted experiments and screening studies into the results of pathogenic tau linked to frontotemporal dementia and Alzheimer's disease.

The mutations added to the MAPT(tau) gene change the amino acid sequence of the protein (R406W, V337M, P301L), which can boost tau aggregation or impact the phosphorylation or binding affinity of tau.

Axol isogenic Alzheimer's disease models and isogenic frontotemporal dementia disease models were co-created with Horizon Discovery, bringing together Horizon's experience in gene editing with Axol's expertise in neural stem cell differentiation and iPSC reprogramming.

Cat. No. Product Name Starting Material Associated Disease
ax0019 Human iPSC-Derived Neural Stem Cells (Female) Fibroblasts (64 Yr Donor) N/A (isogenic control)
       
ax0321 axolGEM iPSC-Derived Neural Stem Cells MAPT R406W HET Fibroblasts (64 Yr Donor) Frontotemporal dementia, parkinsonism & Alzheimer's disease
ax0322 axolGEM iPSC-Derived Neural Stem Cells MAPT V337M HOM Fibroblasts (64 Yr Donor) Frontotemporal dementia & parkinsonism
ax0323 axolGEM iPSC-Derived Neural Stem Cells MAPT V337M HET Fibroblasts (64 Yr Donor) Frontotemporal dementia & parkinsonism
ax0324 axolGEM iPSC-Derived Neural Stem Cells MAPT P301L HOM Fibroblasts (64 Yr Donor) Frontotemporal dementia & parkinsonism
ax0325 axolGEM iPSC-Derived Neural Stem Cells MAPT P301L HET Fibroblasts (64 Yr Donor) Frontotemporal dementia & parkinsonism

 

Neural Cell Culture Media and Reagents

Cell culture media and reagents produced by Axol scientists for enhanced plating, expansion, differentiation and maintenance of neural stem cells and cerebral cortical neurons in a varied range of culture formats and applications. The cell culture reagents are combined into convenient bundles for more simplicity and value.

Cat. No. Product Name Product Description Quantity
ax0101 Neural Stem Cell Media & Reagent Bundle - Expansion and Synchronous Differentiation (System A) Contains all of the neural media and reagents required to expand and synchronously differentiate Axol neural stem cells and maintain the differentiated cortical neurons See Product Page
ax0102 Neural Stem Cell Media & Reagent Bundle - Synchronous Differentiation (System B) Contains all of the neural media and reagents required to synchronously differentiate Axol neural stem cells and maintain the differentiated cortical neurons See Product Page
ax0103 Neural Stem Cell Media & Reagent Bundle - Expansion and Spontaneous Differentiation (System C) Contains all of the neural media and reagents required to expand and spontaneously differentiate Axol neural stem cells and maintain the differentiated neural cells See Product Page
ax0104 Neural Stem Cell Media & Reagent Bundle - Spontaneous Differentiation (System D) Contains all of the neural media and reagents required to spontaneously differentiate Axol neural stem cells and maintain the differentiated neural cells See Product Page
ax0051 ReadyFect Transfection reagent optimized for transfection of NSCs 40 μL

 

About AXOL Biosciences

Axol specializes in human cell culture.

Axol produces high quality human cell products and critical reagents such as media and growth supplements. We have a passion for great science, delivering epic support and innovating future products to help our customers advance faster in their research.

Our expertise includes reprogramming cells to iPSCs and then differentiating to various cell types. We supply differentiated cells derived from healthy donors and patients of specific disease backgrounds. As a service, we also take cells provided by customers (primary or iPSC) and then do the reprogramming (when necessary) and differentiation. Clearly, by offloading the burden of generating cells, your time is freed up to focus on the research. Axol holds the necessary licenses that are required to do iPSC work.

The package wouldn't be complete without optimized media, coating solutions and other reagents. Our in-house R&D team works hard to improve on existing media and reagents as well as innovate new products for human cell culture. We also supply a growing range of human primary cells; making Axol your first port of call for your human cell culture needs.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Nov 12, 2019 at 5:40 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Axol Bioscience Ltd. (2019, November 12). Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Disease. News-Medical. Retrieved on December 06, 2019 from https://www.news-medical.net/whitepaper/20191112/Neural-Stem-Cells-for-Frontotemperal-Dementia-and-Alzheimers-Disease.aspx.

  • MLA

    Axol Bioscience Ltd. "Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Disease". News-Medical. 06 December 2019. <https://www.news-medical.net/whitepaper/20191112/Neural-Stem-Cells-for-Frontotemperal-Dementia-and-Alzheimers-Disease.aspx>.

  • Chicago

    Axol Bioscience Ltd. "Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Disease". News-Medical. https://www.news-medical.net/whitepaper/20191112/Neural-Stem-Cells-for-Frontotemperal-Dementia-and-Alzheimers-Disease.aspx. (accessed December 06, 2019).

  • Harvard

    Axol Bioscience Ltd. 2019. Neural Stem Cells for Frontotemperal Dementia and Alzheimer's Disease. News-Medical, viewed 06 December 2019, https://www.news-medical.net/whitepaper/20191112/Neural-Stem-Cells-for-Frontotemperal-Dementia-and-Alzheimers-Disease.aspx.

Other White Papers by this Supplier